Publications by authors named "Lisa Bodei"

Claim this Profile
D
Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.
Rohit Thummalapalli, Salomon Tendler, Joanne F Chou, Zeynep C Tarcan, Courtney Porfido, Lisa Bodei

JCO Precis Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lesion Absorbed Dose-Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [Lu]Lu-PSMA-617 Radiopharmaceutical Therapy.
Milan Grkovski, Simone S Krebs, Joseph A O'Donoghue, Jonathan Kuten, Audrey Mauguen, Lisa Bodei

J Nucl Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential Clearance of [Lu]Lu-PSMA-617 from Metastatic Prostate Cancer Lesions and Normal Tissues creates a Window for Safe Application of DNA Repair Inhibitors.
James Russell, Milan Grkovski, Joseph A O'Donoghue, Alexandre Franca-Velo, Simone Krebs, Lisa Bodei

medRxiv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of DAXX/ATRX Protein Expression Results in Ischemia Resistance and Radiation Sensitivity in Pancreatic Neuroendocrine Tumor Cells and Is Associated with Improved Response to Trans-Arterial Radioembolization.

Neuroendocrinology· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extravasation Frequency of [Lu]Lu-DOTATATE: Insights and Implications Derived from 1,314 Cycles of Treated Patients-A Single-Site Analysis.
Gunjan Kayal, Finn Augensen, Lisa Bodei, Bae Chu, Harry Marquis

J Nucl Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Symptomatic Prostate-Specific Membrane Antigen PET-Positive Radionecrosis After Multimodality Brain Metastasis-Directed Treatment Including [Lu]Lu-PSMA-617.
Brandon S Imber, Kenny Kwok Hei Yu, Wassim Abida, Luke R G Pike, Milan Grkovski, Lisa Bodei

J Nucl Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update.
Rohan Garje, Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, R Bryan Rumble, Mary-Ellen Taplin, Lisa Bodei

J Clin Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delta-like ligand 3 expression and functional imaging in gastroenteropancreatic neuroendocrine neoplasms.
Rohit Thummalapalli, Salomon Tendler, Joanne F Chou, Zeynep C Tarcan, Courtney Porfido, Lisa Bodei

medRxiv· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reflections on the Demand for PSMA- and SSTR-Targeted Radiopharmaceutical Therapies: Why We Were Wrong (and Why We Will Be Right Eventually).
Johannes Czernin, Lisa Bodei, Irvin Modlin, Jeremie Calais

J Nucl Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dosimetry of [Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial.
Lisa Bodei, Marta Cremonesi, Mahila Ferrari, Erik S Mittra, Harshad R Kulkarni

J Nucl Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges with Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice.
Hossein Jadvar, Amir Iravani, Lisa Bodei, Jeremie Calais

J Nucl Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Update in the management of gastroenteropancreatic neuroendocrine tumors.
Andrew J H Sedlack, Diana Grace Varghese, Amirkia Naimian, Pouria Yazdian Anari, Lisa Bodei

Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence (CoE): Survey from the ENETS lung NET task force.
Anna Koumarianou, Pier Luigi Filosso, Lisa Bodei, Justo P Castano, Lynnette Fernandez-Cuesta

J Neuroendocrinol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imaging with [Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial.
Salomon Tendler, Mark P Dunphy, Matthew Agee, Joseph O'Donoghue, Rania G Aly, Lisa Bodei

Lancet Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuroendocrine Tumors: Beta Labeled Radiopeptides.
Lisa Bodei, Vetri Sudar Jayaprakasam, Bernadette Zhi Ying Wong, Carina Mari Aparici

PET Clin· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a multigenomic liquid biopsy (PROSTest) for prostate cancer in whole blood.
Irvin M Modlin, Mark Kidd, Ignat A Drozdov, Martin Boegemann, Lisa Bodei

Prostate· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis.
Manila Rubino, Giuseppe Danilo Di Stasio, Lisa Bodei, Stefano Papi, Paola Anna Rocca

Endocrine· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial Design.
Ana P Kiess, Joseph O'Donoghue, Carlos Uribe, Lisa Bodei, Robert F Hobbs

J Clin Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiopharmaceuticals for Cancer Diagnosis and Therapy: New Targets, New Therapies-Alpha-Emitters, Novel Targets.
Neil K Taunk, Freddy E Escorcia, Jason S Lewis, Lisa Bodei

Cancer J· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequencing of Somatostatin-Receptor-Based Therapies in Neuroendocrine Tumor Patients.
Jonathan R Strosberg, Taymeyah Al-Toubah, Ghassan El-Haddad, Diane Reidy Lagunes, Lisa Bodei

J Nucl Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toward individualized dosimetry for radiopharmaceutical therapy in day-to-day clinical practice of nuclear oncology: overcoming heterogeneity of radiation-absorbed dose to tumor and critical organs.
Lisa Bodei, R Michael Tuttle, Ravinder K Grewal, Audrey Mauguen, Finn Augensen

Eur J Nucl Med Mol Imaging· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human imaging with [Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate.
Salomon Tendler, Mark P Dunphy, Matthew Agee, Joseph O'Donoghue, Rania G Aly, Lisa Bodei

medRxiv· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lesion Dosimetry for [Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate Cancer.
Milan Grkovski, Joseph A O'Donoghue, Brandon S Imber, George Andl, Cheng Tu, Lisa Bodei

J Nucl Med· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1, Open-label, Dose-Ascending Study to Evaluate the Safety and Tolerability of the Therapeutic Radiopharmaceutical 131I-MIP-1095 for the Treatment of Metastatic Castration-Resistant Prostate Cancer.
Andrew L Laccetti, Lisa Bodei, Joseph A O'Donoghue, Wolfgang A Weber, Michael J Morris

Clin Nucl Med· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SNMMI Consensus Statement on Patient Selection and Appropriate Use of Lu-PSMA-617 Radionuclide Therapy.
Thomas A Hope, Emmanuel S Antonarakis, Lisa Bodei, Jeremie Calais, Amir Iravani

J Nucl Med· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis